TriArm Therapeutics

About TriArm Therapeutics

TriArm Therapeutics is a clinical-stage cell therapy company established in 2018. It was co-founded by James Huang and Jay Zhang. Dr. Zhang, who also serves as Co-CEO, holds a PhD from the University of Utah, completed post-doctoral training at Stanford University, and is a Venture Partner at Panacea Venture. The company's other co-founder is Jim Lu, who serves as the Chief Scientific Officer and previously worked as a reviewer in the cell and gene therapy area at the US FDA. In September 2024, the company appointed Douglas E. Williams, Ph.D., as Chief Executive Officer to guide its next growth phase.

Operating on a global scale, TriArm has its headquarters in San Mateo, California, with additional research and development, manufacturing, and clinical operations hubs in Shanghai, Taipei, and Regensburg, Germany. The company's business model is centered on developing and commercializing next-generation CAR-T cell therapies for cancer and autoimmune diseases. By leveraging its international presence, TriArm conducts investigator-initiated trials (IITs) in regions like China to generate early human data efficiently before pursuing IND applications in the U.S. The company has successfully raised a total of $60 million in venture capital funding, with investors including Panacea Venture, GP Capital (China), Efung Capital, Lombard Odier, and VI Ventures.

TriArm's core technology is its non-viral gene transfer platform, which aims to make CAR-T therapies more accessible and affordable. A key feature is the Fast-in-Time™ (FIT™) manufacturing process, which can produce CAR-T cells in just two days, a significant reduction from the several weeks required by conventional methods. This process not only cuts down on production costs but also yields more potent and persistent T cells. The company has also developed several proprietary platform technologies to enhance its therapies, including the FlexTune™, CD30+ FineTune™, and CD3ε FlowTune™ systems, which improve safety, potency, and the cytokine release profile. Its pipeline includes a lead CD19 CAR-T product for B-cell malignancies, which received FDA clearance for its IND in November 2023, as well as therapies targeting CD30, HER2, and CD70 for various lymphomas and solid tumors.